P
PierianDx
Enables clinical labs to deliver patient-specific diagnosis and treatments
About PierianDx
PierianDx is a pioneering company in the field of precision oncology, focusing on genomic testing and interpretation for cancer treatment. The company operates in the clinical genomics market, providing advanced solutions for analyzing complex genomic variants in somatic (non-inherited) cancers. Their primary clients include hospitals, laboratories, and medical centers that require sophisticated tools to enhance their cancer testing capabilities.
Read full description
PierianDx's business model revolves around offering a comprehensive suite of services and products. These include the Clinical Genomics Workspace (CGW), a platform that integrates genomic data interpretation and reporting, and the Clinical Genomics Knowledgebase, a vast repository of genomic information. Additionally, they provide professional services and educational resources such as webinars featuring clinical genomics experts.
The company generates revenue through subscriptions to its CGW platform, sales of its knowledgebase, and fees for its professional services and educational resources. By partnering with institutions like the University of Vermont Medical Center and TriCore Reference Laboratories, PierianDx ensures that its clients can deliver more accurate and standardized genomic reports, ultimately improving patient outcomes.
PierianDx stands out by offering a unique combination of cutting-edge technology and expert scientific and clinical support. This allows their clients to rapidly and economically build advanced in-house precision medicine programs. Their strategic partnerships, such as the one with the University of Augsburg, further enhance their integrated clinical interpretation and reporting solutions.
At a glance
- Status
- Acquired
- Founded
- 2014
- Headquarters
- St. Louis, United States
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 61.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, DNA, Genetics and genomics, Pipes, Precision Medicine, Health Diagnostics, Spinout, Genome Engineering
- Business model
- SaaS
- Investment activity
- 1 company, latest Oct 2016
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2023 | $0 | — | Velsera | ↗ |
| DEBTDebt | Nov 2021 | $15M | — | SJF Ventures · OrbiMed · RTI International · ATW Partners | — |
Growth signals
Latest recorded traffic for PierianDx is 840 monthly website visits, down 96.3% over the last three months. PierianDx's team declined 39.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Album VC
Health Catalyst
Health Catalyst Capital
ARUP Laboratories
SJF Ventures
ATW Partners
Inova Health System
RTI International
Series B and later1 investor entered at this stage
Other known investors2 additional known investors
Velsera
Washington University in St. Louis
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PierianDx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PierianDx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.